These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21048158)

  • 1. Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives.
    Bianchini EP; Fazavana J; Picard V; Borgel D
    Blood; 2011 Feb; 117(6):2054-60. PubMed ID: 21048158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A chemically-modified inactive antithrombin as a potent antagonist of fondaparinux and heparin anticoagulant activity.
    Fazavana J; Bianchini EP; Saller F; Smadja C; Picard V; Taverna M; Borgel D
    J Thromb Haemost; 2013 Jun; 11(6):1128-36. PubMed ID: 23581397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivated antithrombins as fondaparinux antidotes: a promising alternative to haemostatic agents as assessed in vitro in a thrombin-generation assay.
    Bourti Y; Fazavana J; Armand M; Saller F; Lasne D; Borgel D; Bianchini EP
    Thromb Haemost; 2016 Aug; 116(3):452-60. PubMed ID: 27412396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.
    Lu G; DeGuzman FR; Hollenbach SJ; Karbarz MJ; Abe K; Lee G; Luan P; Hutchaleelaha A; Inagaki M; Conley PB; Phillips DR; Sinha U
    Nat Med; 2013 Apr; 19(4):446-51. PubMed ID: 23455714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa.
    Siddiqui F; Tafur A; Bontekoe E; Iqbal O; Jeske W; Mehrotra S; Hoppensteadt D; Ramacciotti E; Fareed J
    Clin Appl Thromb Hemost; 2020; 26():1076029619895120. PubMed ID: 31914798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors.
    Kalathottukaren MT; Creagh AL; Abbina S; Lu G; Karbarz MJ; Pandey A; Conley PB; Kizhakkedathu JN; Haynes C
    Blood Adv; 2018 Aug; 2(16):2104-2114. PubMed ID: 30135185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Reversal for heparins and new anticoagulant treatments].
    Kortchinsky T; Vigué B; Samama CM
    Ann Fr Anesth Reanim; 2013 Jan; 32(1):37-49. PubMed ID: 23273505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins.
    Wood JP; Baumann Kreuziger LM; Desai UR; Mast AE
    Br J Haematol; 2016 Oct; 175(1):123-32. PubMed ID: 27301751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.
    Kuziej J; Litinas E; Hoppensteadt DA; Liu D; Walenga JM; Fareed J; Jeske W
    Clin Appl Thromb Hemost; 2010 Aug; 16(4):377-86. PubMed ID: 20460347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo.
    Schick BP; Maslow D; Moshinski A; San Antonio JD
    Blood; 2004 Feb; 103(4):1356-63. PubMed ID: 14576044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Hirsh J; Bauer KA; Donati MB; Gould M; Samama MM; Weitz JI
    Chest; 2008 Jun; 133(6 Suppl):141S-159S. PubMed ID: 18574264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats.
    Kalaska B; Miklosz J; Kamiński K; Swieton J; Jakimczuk A; Yusa SI; Pawlak D; Nowakowska M; Szczubiałka K; Mogielnicki A
    J Pharmacol Exp Ther; 2020 Apr; 373(1):51-61. PubMed ID: 31937564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing the anticoagulant activity of ultra-low-molecular-weight heparins using N-acetylglucosamine 6-sulfatase.
    Zhou X; Li L; Linhardt RJ; Liu J
    FEBS J; 2013 May; 280(10):2523-32. PubMed ID: 23374371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External Trigger Free Charge Switchable Cationic Ligands in the Design of Safe and Effective Universal Heparin Antidote.
    La CC; Smith SA; Kalathottukaren MT; Haynes CA; Morrissey JH; Kizhakkedathu JN
    Adv Healthc Mater; 2024 Aug; 13(20):e2400108. PubMed ID: 38537246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents.
    Levi M; Eerenberg E; Kamphuisen PW
    J Thromb Haemost; 2011 Sep; 9(9):1705-12. PubMed ID: 21729240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversing anticoagulants both old and new.
    Warkentin TE; Crowther MA
    Can J Anaesth; 2002; 49(6):S11-25. PubMed ID: 12557411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.
    Hoppensteadt D; Walenga JM; Fareed J; Bick RL
    Hematol Oncol Clin North Am; 2003 Feb; 17(1):313-41. PubMed ID: 12627673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization of enoxaparine-induced bleeding by protamine sulfate.
    Van Ryn-McKenna J; Cai L; Ofosu FA; Hirsh J; Buchanan MR
    Thromb Haemost; 1990 Apr; 63(2):271-4. PubMed ID: 2163553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin.
    Kalaska B; Kaminski K; Sokolowska E; Czaplicki D; Kujdowicz M; Stalinska K; Bereta J; Szczubialka K; Pawlak D; Nowakowska M; Mogielnicki A
    PLoS One; 2015; 10(3):e0119486. PubMed ID: 25781030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.